At a Glance
Urine tests for prostate cancer — such as PCA3, SelectMDx, ExoDx, and MyProstateScore 2.0 — look for genetic markers linked to prostate cancer risk. They are not part of the standard NHS diagnostic pathway and cannot diagnose prostate cancer on their own. At The Focal Therapy Clinic, our experienced consultants review all test results — including any urine biomarker findings — as part of a complete clinical picture that also includes PSA, mpMRI, and biopsy where needed.
Key takeaways
- Not a stand-alone diagnosis: no urine test can confirm prostate cancer by itself — results always need specialist interpretation alongside PSA, MRI, and biopsy.
- Risk assessment tools: urine biomarkers estimate the chance of clinically significant cancer; they are best used in selected cases to support decision making, not replace other tests.
- NHS vs private: urine tests are not part of the standard NHS prostate cancer pathway. NICE NG131 sets out the evidence-based diagnostic route for prostate cancer in the UK.
- False results possible: both false positive and false negative results can occur; urine tests cannot replace MRI or specialist review.
- Home tests carry risk: most basic home urine tests do not reliably detect prostate cancer; advanced biomarker tests still require medical supervision and specialist interpretation.
What is a urine test for prostate cancer?
A urine test for prostate cancer checks your urine for markers linked to prostate cancer cells.
Some tests look for gene activity. Others look for small particles or genetic material released by prostate cells. The aim is to estimate your risk of prostate cancer, especially cancer that may need treatment.
A urine test does not show the exact position of a tumour. It also cannot confirm the grade or stage of cancer. These details usually need MRI and biopsy.
Urine tests are best understood as risk tools. They may help decide whether further tests are needed.
How do urine tests work?
Different urine tests work in different ways. Some urine tests are collected after a prostate examination or prostate massage. This is usually done during a digital rectal examination (DRE). The pressure can help release prostate cells and genetic material into the first urine passed after the examination. Other urine tests do not require a DRE, so the collection method depends. The sample is sent to a laboratory, which then checks for prostate cancer-related markers.
Your result is not read in isolation. Your specialist will usually consider it alongside:
- Age
- PSA
- Family history
- Prostate size
- MRI findings
- DRE findings (if applicable)
- Any symptoms
- Any biopsy history
Some tests produce a score. A higher score may suggest a higher chance of prostate cancer. It does not prove that cancer is present.
What can urine tests detect?
Urine tests may detect markers linked to prostate cancer. Some tests aim to estimate the risk of clinically significant prostate cancer. This difference matters as many cancers grow slowly, and these may never cause harm during a man’s lifetime. Doctors try to find cancers that are more likely to grow, spread or need treatment.
A urine test may help with this risk assessment, but cannot replace the full diagnostic pathway.
| What the test may help assess | What this means |
|---|---|
| Risk of prostate cancer | May suggest whether further tests are worth considering |
| Risk of significant cancer | May help estimate the chance of higher-grade disease |
| Risk after previous negative biopsy | May add information if concern remains |
| Overall risk picture | May support decisions when used with PSA, MRI and clinical findings |
Can a urine test replace a PSA test?
A urine test does not replace a PSA blood test.
The PSA blood test remains the most common first test for prostate cancer risk. It is widely used in primary care and specialist practice.
PSA is not perfect. It can be raised for reasons other than cancer, such as an enlarged prostate, infection or recent prostate stimulation. It can also miss some cancers.
Urine tests may provide extra information in selected cases. They are not the usual first step. They are not a replacement for PSA, MRI or biopsy.
You can read more about where different tests fit in our guide to the most accurate test for prostate cancer.
What is PCA3?
PCA3 is one of the older urine biomarker tests for prostate cancer.
PCA3 stands for prostate cancer gene 3. This gene is more active in many prostate cancer cells. A PCA3 test measures this activity in urine.
The test usually needs a DRE before the urine sample. This helps move prostate cells into the urine.
A higher PCA3 score may suggest a higher chance of prostate cancer. However, it is important to note that PCA3 is not used routinely in the NHS. NICE does not recommend the PCA3 assay for people being investigated after a negative or inconclusive prostate biopsy; the European Association of Urology also states that the clinical value of PCA3 for biopsy decision-making remains unclear.
Get Expert Advice & The Latest Research
Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.
What is MyProstateScore 2.0?
MyProstateScore 2.0, often called MPS2, is a newer urine test. It measures a panel of 10+ gene markers linked to prostate cancer and higher-grade disease.
Research suggests that MPS2 may help identify men who are less likely to have clinically significant prostate cancer. This could reduce some unnecessary biopsies in selected groups.
However, MPS2 is also not part of routine NHS prostate cancer diagnosis. It is mainly discussed in research and commercial testing settings. It also does not replace MRI or biopsy. Your specialist still needs to interpret the result in the context of your full clinical picture.
Can urine tests help avoid a biopsy?
In selected men, a urine test may help avoid an unnecessary biopsy. This is most likely when the result suggests a low risk and other findings are reassuring.
However, urine tests must not be used to avoid biopsy when the risk remains concerning. If your PSA, MRI, DRE or clinical history suggests a significant risk, biopsy may still be needed. A biopsy also shows the cancer grade, which helps guide treatment decisions.
Are home urine tests available?
Some home tests are marketed for prostate health. These need caution.
Many basic home urine kits only check for blood in the urine. Invisible blood in urine is not a reliable sign of prostate cancer. Visible blood in urine needs medical review, but it is more often linked to other causes.
Some advanced urine biomarker tests may involve home or clinic collection depending on the test provider. These tests still need medical interpretation. A result without specialist advice can be misleading.
If you are worried about prostate cancer, it is safer to speak with your GP or a prostate cancer specialist.
Limitations of urine tests
No urine test for prostate cancer is perfectly accurate.
A false positive result may suggest higher risk when cancer is not present. This can lead to anxiety and more testing.
A false negative result may suggest low risk when significant cancer is present. This is why urine tests cannot replace MRI, biopsy or specialist review.
There are also practical issues. Availability, cost and test performance vary. Results may depend on the test used, the cut-off chosen, and the group of men being tested.
Current European guidance recognises that some urine and blood biomarkers may help with risk assessment. However, no specific urine biomarker test is recommended for routine clinical practice at present.
What happens if prostate cancer is suspected?
If prostate cancer is suspected, the next step is risk assessment. This usually considers:
- PSA
- MRI findings
- Biopsy grade
- Cancer stage
- Cancer volume
- General health
- Personal priorities
Treatment is not based on a urine test alone. Some men may be suitable for active surveillance. Others may need surgery, radiotherapy or hormone treatment. Selected men with localised prostate cancer may wish to discuss focal therapy.
Focal therapy treats the known cancer area rather than the whole prostate. It aims to reduce damage to nearby tissue and aims to preserve urinary continence and erectile function. Suitability depends on cancer position, grade, volume, MRI findings and biopsy results. The best decision is made after careful review by experienced prostate cancer specialists.
FAQs
References
Prostate Cancer UK. (2023). The problem with home urine tests for prostate cancer. Available at: https://prostatecanceruk.org/about-us/news-and-views/2023/09/problem-with-home-urine-tests
Prostate Cancer UK. (n.d.). Other tests. Available at: https://prostatecanceruk.org/prostate-information-and-support/prostate-tests/other-tests
European Association of Urology. (2026). EAU Guidelines on Prostate Cancer. Available at: https://uroweb.org/guidelines/prostate-cancer
National Institute for Health and Care Excellence. (2021). Prostate cancer: diagnosis and management (NG131). Available at: https://www.nice.org.uk/guidance/ng131
NHS. (2025). Tests and next steps for prostate cancer. Available at: https://www.nhs.uk/conditions/prostate-cancer/tests-and-next-steps/
Cancer Research UK. (n.d.). Tests for prostate cancer. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/getting-diagnosed/tests-for-prostate-cancer
